ACADIA Pharmaceuticals Inc. (ACAD)

22.21
3.80 14.00
NASDAQ : Health Technology
Prev Close 25.97
Open 22.50
Day Low/High 21.56 / 23.20
52 Wk Low/High 12.77 / 28.67
Volume 8.73M
Avg Volume 965.40K
Exchange NASDAQ
Shares Outstanding 144.17M
Market Cap 3.71B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
ACADIA Pharmaceuticals (ACAD) Lags In Post-Market Trading

ACADIA Pharmaceuticals (ACAD) Lags In Post-Market Trading

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market laggard candidate

ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Acadia Drug Approval May Entice Biogen, Teva as Buyers

Acadia Drug Approval May Entice Biogen, Teva as Buyers

Analysts believe that the biotech company could fetch up to $6 billion in a sale since its compound will be the first in a new class of anti-psychotic drugs.

Acadia Pharmaceuticals Stock Has Fallen Too Far Recently

Acadia Pharmaceuticals Stock Has Fallen Too Far Recently

Acadia shares have fallen significantly since the company's Nuplazid drug received FDA approval. Here's why they're worth more.

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 11, 2016

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 11, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Why Acadia Pharma's First Drug Approval Isn't Moving Stock Higher

Why Acadia Pharma's First Drug Approval Isn't Moving Stock Higher

A number of factors help explain the less-than-celebratory reaction to the approval of Acadia Pharma's first drug, Nuplazid.

8 Stocks Spiking on Big Volume

8 Stocks Spiking on Big Volume

Here's a technical look at how to trade eight stocks rising on unusual volume recently.

Analysts' Actions -- Amazon, Walmart, Acadia, International Paper and More

Analysts' Actions -- Amazon, Walmart, Acadia, International Paper and More

Here are Tuesday's top research calls, including downgrades for Acadia, International Paper and Walmart, and an upgrade for Amazon.

Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug

Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug

The FDA approved Nuplazid, a drug used to treat Parkinson's disease psychosis and the related hallucinations and delusions.

ACADIA Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 5, 2016

ACADIA Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 5, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

4 Possible Biotech M&A Targets

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.

ACADIA Pharmaceuticals (ACAD) Shows Signs Of Being Water-Logged And Getting Wetter

ACADIA Pharmaceuticals (ACAD) Shows Signs Of Being Water-Logged And Getting Wetter

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

ACADIA Pharmaceuticals (ACAD) Stock Down Despite Nuplazid Approval

ACADIA Pharmaceuticals (ACAD) Stock Down Despite Nuplazid Approval

ACADIA Pharmaceuticals (ACAD) gained FDA approval for its Nuplazid drug which treats hallucinations related to Parkinson’s disease psychosis.

NUPLAZID™ (pimavanserin) Bottle (Photo: Business Wire)

NUPLAZID™ (pimavanserin) Bottle (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

3 Red Flags to Lightly Consider

The markets are telling traders to take profits, tighten stops and raise cash. But despite these observations, it’s unlikely the bottom will drop out any time soon.

ACADIA Pharmaceuticals (ACAD) Flagged As Strong On High Volume

ACADIA Pharmaceuticals (ACAD) Flagged As Strong On High Volume

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

'Mad Money' Lightning Round: Take Costco Over Walmart

'Mad Money' Lightning Round: Take Costco Over Walmart

Cramer is not a big fan of Toyota and is avoiding Chesapeake Energy.

Jim Cramer's 'Mad Money' Recap: Maybe the Government Did Some Good After All

Jim Cramer's 'Mad Money' Recap: Maybe the Government Did Some Good After All

By blocking the Pfizer-Allergan and Halliburton-Baker Hughes mergers, the Treasury Department unleashed a wave of takeover speculation, Cramer says.

ACADIA Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference On April 12, 2016

ACADIA Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference On April 12, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena

Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stock investing.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager

Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager

Shares of Acadia Pharmaceuticals popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

Acadia's Parkinson's drug Nuplazid clears key hurdle

Acadia's Parkinson's drug Nuplazid clears key hurdle

Acadia could rake in $2 billion in revenue from Nuplazid

Why Acadia (ACAD) Stock is Still Soaring Today

Why Acadia (ACAD) Stock is Still Soaring Today

Acadia (ACAD) shares are flying on heavy trading volume Wednesday as the company's key drug in its portfolio is one step closer to being approved by the FDA.

4 Big-Volume Stocks to Trade for Big Gains

4 Big-Volume Stocks to Trade for Big Gains

These stocks are seeing unusually large trading volume today. Here's what to do with them now.

Acadia (ACAD) Stock Skyrockets, Parkinson's Disease Drug Backed by FDA Advisory Panel

Acadia (ACAD) Stock Skyrockets, Parkinson's Disease Drug Backed by FDA Advisory Panel

Acadia (ACAD) shares are surging on Wednesday after the advisory panel to the Food and Drug Administration voted in favor of a key drug in the company's portfolio.

TheStreet Quant Rating: D (Sell)